Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

28.800
+0.0600.21%
Volume:6.40M
Turnover:186.59M
Market Cap:10.20B
PE:-32.36
High:29.960
Open:29.620
Low:28.540
Close:28.740
52wk High:58.450
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:2.55
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.67
PE(LYR):-32.36
PS:3.62

Loading ...

Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth

Deep News
·
Aug 25

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Stock News
·
Aug 25

Movement Alert|EVEREST MED Rises 5.14% in Regular Trading, mRNA Catalyst Sustains as Broker Reaffirms Buy Rating

Market Focus
·
Aug 25

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

Deep News
·
Aug 24

Movement Alert|EVEREST MED Rises 5.28% in Regular Trading, Technical Rebound as mRNA Catalyst Lingers and Broker Maintains Buy Rating

Market Focus
·
Aug 24

Movement Alert|EVEREST MED Intraday Decline 6.77%, Profit-Taking After Previous Session mRNA-Fueled 41% Surge

Market Focus
·
Aug 21

Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Simply Wall St.
·
Aug 21

Medical Stocks Surge on Breakthrough News: Everest Med Jumps Over 70% Intraday, Wuxi Apptec Hits New High, and ETFs See Explosive Volume

Deep News
·
Aug 20

HK Movers | Pharma Stocks Surge With 3D Medicines up 68%, CanSino Biologics up 52%

Tiger Newspress
·
Aug 20

EVEREST MED Surges Over 89% at Market Open on Strong First-Half Revenue of 1.148 Billion Yuan, Up 157% Year-on-Year

Deep News
·
Aug 20

Movement Alert|EVEREST MED Rises 47.06% in Regular Trading, mRNA Vaccine Breakthrough and Strong Interim Results Drive Dual Catalyst Rally

Market Focus
·
Aug 20

Everest Medicines Surges 15% as Moderna's Cancer Vaccine Breakthrough Revitalizes mRNA Sector

Stock News
·
Aug 20

EVEREST MED Posts Strong Interim Results with Revenue Soaring 157% as Nefecon Commercial Launch and Real-World Data Gain Momentum

Stock News
·
Aug 19

Everest Medicines H1 Revenue RMB 701.7 Million

THOMSON REUTERS
·
Aug 19

Everest Medicines FY26 H1 Net Loss Narrows to RMB 5.9 Million; Revenue More than Doubles to RMB 1.15 Billion

Reuters
·
Aug 19

17 Drugmakers Announce Major Executive Reshuffles in Half a Month

Deep News
·
Aug 17

Everest Medicines Files Board, Board Committee Member List with Disclosure Responsibilities

Reuters
·
Aug 14

Everest Medicines Appoints Yue Wang as Non-Executive Director

Reuters
·
Aug 14

Earning Preview: EVEREST MED this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Aug 13

We Might See A Profit From Everest Medicines Limited (HKG:1952) Soon

Simply Wall St.
·
Aug 08